A new drug combo for advanced liver bile duct cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new combination of three drugs (adebrelimab, surufatinib, and liposomal irinotecan) given directly into the liver artery for advanced intrahepatic cholangiocarcinoma. The goal is to see if this approach can shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a specific type of liver cancer called intrahepatic cholangiocarcinoma.
- You have not had any prior cancer treatment (like chemotherapy or surgery).
- You are in fairly good health — able to do most daily activities (ECOG score 0 or 1).
- Your liver and kidney function test results need to be within certain ranges (study staff will check).
- You must not have an autoimmune disease (like lupus or rheumatoid arthritis) or be on strong immune-suppressing medications.
- You are willing to use effective birth control if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy directly into the liver artery, an immunotherapy drug, and a targeted therapy pill before surgery for a type of bile duct cancer that has a high chance of coming back. The goal is to see if this approach can improve outcomes for patients whose cancer is still removable but has certain high-risk features.
This trial tests a combination of two drugs (surufatinib and toripalimab) plus a chemotherapy infusion directly into the liver artery (HAIC) for people with bile duct cancer that cannot be removed by surgery or has spread. The goal is to see if this combination can shrink tumors or slow the cancer.
This study tests a combination of liver-directed therapy (D-TACE-HAIC), an immunotherapy drug (Envafolimab), and a targeted therapy pill (Lenvatinib) for people with a type of liver cancer (intrahepatic cholangiocarcinoma) that cannot be surgically removed. The goal is to see if this combination can shrink or control the cancer.
This trial tests if adding a combination of immunotherapy (adebrelimab), a targeted drug (apatinib), and chemotherapy into the liver artery (HAIC) before and after surgery can help people with resectable intrahepatic cholangiocarcinoma (a type of bile duct cancer). The goal is to see if this approach improves outcomes.
This trial tests a combination of chemotherapy (gemcitabine and cisplatin) with the targeted therapy lenvatinib and the immunotherapy adebrelimab for people with advanced bile duct cancer that cannot be removed by surgery. It aims to see if this combination works better than standard treatments.
This trial tests a combination of a targeted drug (lenvatinib), an immunotherapy (PD-1 inhibitor), and chemotherapy given directly into the liver's blood supply for people with advanced intrahepatic cholangiocarcinoma (a type of bile duct cancer that starts in the liver). The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Hear when a new Intrahepatic Cholangiocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.